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INTRODUCTION
Gastrointestinal metastases from invasive lobular breast car-
cinoma (ILC) are uncommon and usually occur years after the 
primary tumor. According to findings of large autopsy studies, 
the most frequent metastatic gastrointestinal (GI) sites are stom-
ach, followed by small bowel and colon [1]. Interestingly, GI 
metastases were found to be the first manifestation of disease 
in clinically occult primary breast carcinoma. As ILC may pres-
ent only as an asymmetric density rather than a dominant tu-
mor mass [2], it could be missed on routine mammography 
evaluation. Histopathological and immunohistochemical anal-
ysis of biopsy specimen taken from GI metastatic sites are key 
in determining primary tumors [3]. Although GI metastases 
from ILC have been rare, the recognition of these entities is 
very important for making prompt diagnosis and providing 
appropriate treatment. Herein, we present a case of a patient 
with peritoneal carcinomatosis as a first sign of lobular breast 
carcinoma, with recurrence of disease six years later as rectal 
metastasis.
CASE REPORT
A 47-year-old premenopausal woman was admitted to our 
hospital due to abdominal distension, intermittent abdominal 
pain, and prolonged constipation. During a routine ultrasound 
(US) evaluation, ascites and complex cystic ovarian masses were 
detected. Colonoscopy revealed two extraluminal compres-
sions, one in the region of proximal rectum and the other one 
in rectosigmoidal junction without any mucosal changes. Fur-
ther abdominal computerized tomography (CT) examination 
showed peritoneal and omental implants, ascites, and bilateral 
ovarian cysts. Since the patient had complex ovarian cysts and 
ascites compatible with carcinomatosis, a diagnosis of ovarian 
cancer with peritoneal dissemination had been suspected. 
The patient underwent total hysterectomy and bilateral sal-
pingo-oophorectomy. Histological examination of ovarian and 
uterine tissue showed no malignant cells, while analysis of bi-
opsy specimens taken from peritoneal and omentum implants 
revealed single-file strands of infiltrating small tumor cells, dis-
persed in the fibrous matrix with rare cells of the “signet-ring” 
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Gastrointestinal metastases from invasive lobular breast cancer 
are uncommon with the stomach and small intestines being the 
most common metastatic sites. Peritoneal and rectal metastases 
are very rare and only rarely occur as the first manifestation of 
disease. We herein report the case of a 47-year-old woman who 
presented with abdominal carcinomatosis as a first sign of inva-
sive lobular breast carcinoma (ILC). Identifying the most impor-
tant immunohistochemical markers for ILC: gross cystic disease 
fluid protein 15, estrogen and progesterone receptors enabled a 
correct diagnosis. After a six year disease-free period, relapse oc-
curred with severe obstruction due to rectal metastasis from lob-
ular breast carcinoma. Since there was no widespread metas- 
tatic disease, surgery with concomitant hormonal therapy was 
performed.
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type (Figure 1A). Further immunohistochemistry staining 
showed that 95% of cells were highly positive for cytokeratin 7 
(CK7) and gross cystic disease fluid protein 15 (GCDFP-15). 
Further, estrogen (ER) and progesterone receptors (PR) were 
positive in 80% of tumor cells. These findings were consistent 
with a diagnosis of ILC with metastases to the peritoneum and 
omentum. Although mammography did not show the prima-
ry tumor, US examination revealed tumefaction in the left 
breast. A breast tumor biopsy showed grade 3 ILC (Figure 1B). 
The patient’s human epidermal growth factor receptor 2 (HER2) 
status was negative: immunohistochemistry showed HER2: 2+, 
but chromogenic in situ hybridization analysis demonstrated 
that there was no gene amplification. Complete remission with 
regression of peritoneal and omental implants was achieved 
after chemotherapy which included fluorouracil, doxorubicine, 
and cyclophosphamide (FAC protocol). Levels of the cancer 
antigen 15-3 (CA 15-3), which was initially 66 U/mL (normal 
value <31), lowered to 19 U/mL. The patient continued on 
tamoxifen (20 mg/day) after cessation of chemotherapy with 
regular controls every six months. 
After six years of disease-free period, the patient was admit-
ted to our hospital for the second time because of prolonged 
constipation, early satiety, and weight loss. Rectosigmoidosco-
py revealed thickening and rigidity of the rectal wall, with ste-
nosis of the lumen 10 cm above the anal verge. Further exami-
nation with abdominal and pelvic magnetic resonance imaging 
(MRI) showed a stage 3 rectal tumor, with extension of tumor 
tissue through the muscle layer and obliteration of the interface 
between the muscle and perirectal fat (Figure 2). In order to 
determine the presence of distant metastases, the patient un-
derwent a positron-emission tomography examination, which 
demonstrated a high uptake of fluorine
18-fluoro-deoxy-glucose 
(
18F-FDG) in the rectal wall, with an standardized uptake val-
ue (SUVmax) of 9.8 (Figure 3). Histopathological analysis of 
biopsy specimens taken during rectosigmoidoscopy showed 
diffuse infiltration of tumor cells along the rectal wall, some of 
them with the presentation of the “signet-ring cell” type (Fig-
ure 4A). Immunohistochemistry revealed that the tumor cells 
A B
Figure 1. Histological features of 
peritoneal metastasis (A) and breast 
biopsy: invasive lobular breast car-
cinoma (B) (H&E stain, ×100).
A C B
Figure 2. Turbo-spin-echo fat suppression T1 weighted (A) and turbo-spin-echo T2 weighted axial (B) and sagittal (C) MR image show a stage T3 
rectal tumor. The tumor has intermediate signal intensity between the high signal intensity of the fat tissue and the low signal intensity of the muscular 
layer. Tumor signal intensity extends through the muscle layer into the perirectal fat, with obliteration of the interface between muscle and perirectal 
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were reactive for CK7, GCDFP-15, CA 15-3, and ER (Figure 
4B). On the basis of these findings, a diagnosis of rectal metas-
tasis from lobular breast carcinoma was made. Clinical and 
mammography examination of the breasts excluded loco-re-
gional relapse or second primary cancer in the contralateral 
breast. Since our patient had already developed stenosis and 
serious obstruction, rectal metastatic involvement was treated 
surgically with a colo-ano “pull-through” anastomosis, and sub-
sequent operation after five months for closing a colostomy. In 
addition, daily treatment with aromatase inhibitor (anastro-
zole, 1 mg/day) was administered. After a one year follow-up 
period, the patient was asymptomatic and regular US and CT 
examinations have not shown a relapse of the disease. The clin-
ical course of the disease has been depicted in Figure 5.
DISCUSSION
Gastrointestinal metastases from lobular breast carcinoma 
are infrequently recognized clinically, especially when occur-
ring as a first manifestation of the disease. The predilection of 
ILC for metastasizing in the GI tract may be explained by its 
distinct histological and biological features. Berx et al. [4] found 
that the majority of ILC lack cohesiveness due to inactivation 
of E-cadherin, a cell-to-cell adhesion protein. Thus, metastatic 
spread could happen early in the disease course with barely 
detectable primary tumors as in our case. On the other hand, 
occurrence of GI metastases years after a primary tumor is 
probably related to ILC HER2 status. Overexpression of HER2 
receptor in breast cancer has been associated with fast growth 
and a poorer prognosis [5]. ILC is typically a HER2 negative 
tumor which is consistent with its biological behavior, and pa-
tient surveillance. 
Clinical manifestations of GI metastases from ILC have been 
quite diverse with nonspecific symptoms usually mimicking 
primary GI and pelvic malignancies. As described in previous 
reports, the most common initial diagnosis in patients with 
peritoneal metastases without known primary tumor has been 




18F-FDG-PET/CT findings. (A) Axial computerized tomography 
(CT) image shows circumferential rectal wall thickening. (B) Axial CT at-
tenuation-colorectal positron-emission tomography (PET) image and 
axial fused PET/CT image (C) revealed area of increased fluorine
18-fluo-
ro-deoxy-glucose (
18F-FDG) uptake in rectal wall (standardized uptake 
value, SUVmax=9.8). (D) Increased uptake of 
18F-FDG is also seen on 
maximum intensity projection reconstruction of CT attenuation-correct-
ed PET image.
Figure 4. Histological and immunohistochemical features of rectal biop-
sy. (A) Diffuse carcinomatous infiltration of the rectal wall, mostly in the 
basal layer of mucosa and superficial submucosa. (B) Immunohisto-
chemistry depicted strong immunoreactivity to gross cystic disease fluid 
protein 15 antigen (Immunohistochemical stain, ×100).
A B
Figure 5. Clinical course of metastatic invasive lobular breast carcino-
ma. Signs and symptoms (☆) of the disease at the time of presentation 
and six years later. At first the patient underwent hysterectomy and sal-
pingo-oophorectomy because of suspected ovarian cancer with perito-
neal dissemination. After the diagnosis of metastatic invasive lobular 
breast cancer was made the patient received chemotherapy (FAC pro-
tocol) and tamoxifen remaining disease free for six years. The recurrence 
of disease was treated surgically with concomitant hormone therapy.250  DjordjijeSaranovic,etal.
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with ascites and bilateral ovarian masses, and a diagnosis of 
ovarian cancer was made. Only after histopathological confir-
mation of metastatic breast cancer, the primary tumor was dis-
covered. Although a median survival of a maximum 26 months 
for patients with peritoneal metastases from ILC has been pre-
viously reported [7], our patient experience six years of a dis-
ease free state. Given the fact that this was a highly endocrine 
responsive lobular breast cancer, it may be assumed that long 
disease free interval was mainly the result of a positive effect 
of endocrine therapy, ovariectomy, and tamoxifen [8]. More-
over, in previous studies peritoneal metastases were shown to 
be late with respect to manifestation of widespread disease, 
while in this report peritoneal carcinomatosis was the first sign 
of disease without other detectable metastases.
Rectal metastases from lobular breast carcinoma occur usu-
ally 5 to 7 years after primary tumors [9]. The most usual man-
ifestation of rectal metastasis has been diffuse infiltration lead-
ing to thickening and rigidity of rectal wall [10], as in this re-
port. Since clinical presentation of both rectal and peritoneal 
metastases is quite nonspecific, pathohistological and immu-
nohistochemical analysis are the most important diagnostic 
tools in determination of diagnosis. Microscopically, metasta-
ses from ILC consist of spindle-shaped cells usually of the “sig-
net-ring” cell type that show a single-file growth pattern with 
no dominant mass, as observed in our study [11]. The most 
important markers for ILC are GCDFP-15, ER and PR, which 
proved to be positive in biopsy specimens from peritoneal im-
plants in our patient. Furthermore, tumor cells from the rectal 
wall were highly positive for CK7, GCDFP-15, and ER and neg-
ative for CK20 and PR markers. As stated previously, positivity 
for CK7 and negativity for CK20 suggest a metastasis, while 
CK7-/CK20+ profile characterizes a large bowel primary tumor 
[12]. To our knowledge, peritoneal carcinomatosis as a first 
manifestation of ILC with recurrence of disease in the form of 
rectal metastasis six years later in a single patient has not yet 
been described.
In conclusion, in any case of peritoneal carcinomatosis of 
unknown origin, ILC should be considered in the differential 
diagnosis. Furthermore, in patients with prolonged constipa-
tion and previous breast cancer history, awareness of rectal me-
tastasis is necessary. 
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